Header Logo

Connection

Dusan Stefoski to Risk Assessment

Back to Details
This is a "connection" page, showing publications Dusan Stefoski has written about Risk Assessment.
Dusan Stefoski
Connection Strength
0.023
Risk Assessment
  1. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet. 2013 Jun 22; 381(9884):2167-75.
    View in: PubMed
    Score: 0.023
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.